These data suggest that increasing NTF2 expression is sufficient to at least partially revert metastatic melanoma cells to a more primary melanoma character, supporting the idea that NTF2 is a melanoma tumor suppressor and potential new therapeutic target to treat metastatic melanoma. The gene discussed is NUTF2; the disease is metastatic melanoma.